Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Otsuka Pharmaceutical and H Lundbeck have entered a long-term agreement to develop and commercialize five innovative psychiatric and neuroscience products across the globe.
Subscribe to our email newsletter
The collaboration covers two late stage compounds from Otsuka- aripiprazole depot formulation and OPC-34712.
Aripiprazole depot formulation for schizophrenia is a sterile, lyophilized cake that when reconstituted with sterile water for injection, forms an injectable suspension.
OPC-34712 is a novel investigational psychotherapeutic compound used to treat schizophrenia and major depressive disorder (MDD).
As per the deal, Lundbeck will make an upfront payment upon signing of $200m.
Otsuka will receive around $1.4bn from Lundbeck as upfront payment and development and regulatory milestone payments.
For aripiprazole depot formulation, Lundbeck will receive 50% of net sales in Europe and Canada and 20% of net sales in the US from Otsuka.
In addition, for OPC-34712, Lundbeck will receive 50% of net sales in Europe and Canada and 45% of net sales in the US from Otsuka.